Galectin Therapeutics

Galectin Therapeutics (Nasdaq:GALT) is developing promising carbohydrate-based therapies for the treatment of fibrotic liver disease and cancer based on the Company's unique understanding of galectin proteins, key mediators of biologic function. We are leveraging extensive scientific and development expertise as well as established relationships with external sources to achieve cost effective and efficient development. We are pursuing a clear development pathway to clinical enhancement and commercialization for our lead compounds in liver fibrosis and cancer.

Find a broker to begin trading GALT now

Company Name Galectin Therapeutics
Market/Symbol NASDAQ: GALT
Recent Price
Market Cap $164.65M
Avg. Daily Vol. (3m) 830,119
Price/Book N/A
Price/Cash Flow N/A
As of Mar. 20, 2018
*Source: QuoteMedia

Begin trading GALT

 Find Broker



Galectin Therapeutics Latest News

Ask the CEO

Historical SEC Filings

Date Form Title
Feb 06, 2018 8-K 8-K - Current report
Jan 04, 2018 8-K 8-K - Current report
Dec 19, 2017 8-K 8-K - Current report
Dec 19, 2017 8-K/A 8-K/A [Amend] - Current report
Dec 18, 2017 8-K 8-K - Current report
Dec 05, 2017 8-K 8-K - Current report
Nov 13, 2017 8-K 8-K - Current report
Nov 07, 2017 DEF 14A DEF 14A - Other definitive proxy statements
Nov 07, 2017 8-K 8-K - Current report
Nov 07, 2017 10-Q 10-Q - Quarterly report [Sections 13 or 15(d)]

Receive GALT Email Alerts

*By entering your information you agree to our privacy policy.

"I work with many of the companies that would be RedChip companies. And we certainly ascribe to the same view that the RedChip Companies do, which is Discovering Tomorrow's Blue Chips Today."

  • Bob McCooey, Senior Vice President The NASDAQ Stock Market